Segesterone acetate/ethinylestradiol
| Combination of | |
|---|---|
| Segesterone acetate | Progestogen |
| Ethinylestradiol | Estrogen |
| Clinical data | |
| Trade names | Annovera |
| Other names | EE/SGA; EE/SA |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a604032 |
| License data | |
| Routes of administration | Intravaginal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera among others, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin; and ethinylestradiol, an estrogen.[2][4][5] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[2][6]
The ring is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[7] Unlike NuvaRing, another vaginal ring contraceptive, the combination ring does not need to be refrigerated before being dispensed and can be stored at room temperature up to 30 degrees Celsius.[2]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD.[6] It was approved for medical use in the United States in August 2018,[8] and in Canada in December 2024.[1]
See also
References
- ^ a b "Ringza product information". Health Canada. 18 December 2024. Retrieved 26 December 2024.
- ^ a b c d "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
- ^ "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 8 August 2024. Retrieved 26 December 2024.
- ^ Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.
- ^ Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.
- ^ a b "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control" (Press release). TherapeuticsMD. 10 August 2018. Retrieved 10 October 2020 – via Business Wire.
- ^ "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDA) (Press release). 10 August 2018. Archived from the original on 4 May 2019. Retrieved 10 October 2020.
- ^ "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Archived from the original on 11 April 2021. Retrieved 10 October 2020.